文献速递类风湿关节炎

托珠单抗与阿巴西普治疗类风湿关节炎的心血管风险无差异:多数据库队列研究

No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2018-03-22

该多数据库队列研究比较了类风湿关节炎患者新启用托珠单抗与阿巴西普的心血管安全性,主要终点为心肌梗死或卒中住院的复合心血管终点。在三个数据库中,托珠单抗组与阿巴西普组的复合心血管事件风险相似,合并HR为0.82(95%CI:0.55-1.22)。结论认为两组心血管事件风险无差异。

要点

  • 托珠单抗组与阿巴西普组复合心血管事件风险相似,合并HR为0.82(95%CI:0.55-1.22)。
  • 复合心血管事件发生率托珠单抗组为每100人年0.37至1.64,阿巴西普组为0.59至1.69。
  • 研究覆盖Medicare、IMS PharMetrics和MarketScan三个数据库,托珠单抗组6237例倾向评分匹配至阿巴西普组14685例。

核心结论

  • 该多数据库队列研究发现,新启用托珠单抗与阿巴西普的类风湿关节炎患者心血管事件风险无差异。

研究设计与样本

  • 多数据库队列研究,使用Medicare(2010-2013)、IMS PharMetrics(2011-2014)和MarketScan(2011年至2015年6月)数据。
  • 纳入年龄≥18岁、连续入组≥365天后新启用托珠单抗或阿巴西普的类风湿关节炎患者。
  • 主要终点为心肌梗死或卒中住院的复合心血管终点。
  • 为控制超过60个混杂因素,托珠单抗启用者按可变比例1:3在各数据库内与阿巴西普启用者进行倾向评分匹配。
  • 采用固定效应模型合并各数据库特异性风险比(HR)。

主要发现

  • 复合心血管事件每100人年发生率在托珠单抗组为0.37(PharMetrics)至1.64(Medicare),在阿巴西普组为0.59(PharMetrics)至1.69(Medicare)。
  • 两个组的复合心血管事件风险在所有三个数据库中相似,托珠单抗 versus 阿巴西普启用者的合并HR为0.82(95%CI:0.55-1.22)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: While tocilizumab may increase serum lipid levels, recent studies do not suggest a link between tocilizumab use and clinical cardiovascular risk in patients with rheumatoid arthritis (RA). METHODS: To compare cardiovascular safety of tocilizumab with abatacept, we conducted a cohort study using data from Medicare (2010-2013), IMS PharMetrics (2011-2014) and MarketScan (2011-6/2015). RA patients aged ≥18 years who newly started tocilizumab or abatacept entered the cohort on the day of their first use of tocilizumab or abatacept after a continuous enrollment period for ≥365 days. The primary outcome was a composite cardiovascular endpoint of hospitalization for myocardial infarction or stroke. To control for more than 60 confounders, tocilizumab starters were propensity score (PS)-matched to abatacept starters with a variable ratio of 1:3 within each database. A fixed-effects model combined database-specific hazard ratios (HR). RESULTS: We included 6237 tocilizumab starters PS-matched to 14,685 abatacept starters in all three databases. Mean age was 72 years in Medicare, 51 in PharMetrics and 53 in MarketScan. The incidence rate of the composite cardiovascular events per 100 person-years ranged from 0.37 (PharMetrics) to 1.64 (Medicare) in the tocilizumab group and from 0.59 (PharMetrics) to 1.69 (Medicare) in the abatacept group. The risk of the composite cardiovascular events was similar between the two groups across all three databases, with a combined HR of 0.82 (95% CI: 0.55-1.22) in tocilizumab versus abatacept starters. CONCLUSIONS: This multi-database cohort study found no difference in the risk of cardiovascular events in RA patients who newly started tocilizumab versus abatacept.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Kim SC, Solomon DH, Rogers JR, et al. No difference in cardiovascular risk of tocilizumab versus abatacept for rheumatoid arthritis: A multi-database cohort study. Semin Arthritis Rheum. 2018. PMID: 29673963. doi:10.1016/j.semarthrit.2018.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。